Japan Approves Padcev, Entresto’s Hypertension Use, Lilly’s RET Inhibitor and More

Japan’s Ministry of Health, Labor and Welfare (MHLW) on September 27 approved a batch of new medicines and additional indications including Astellas Pharma’s antibody-drug conjugate (ADC) Padcev (enfortumab vedotin) and the label expansion of Novartis’ Entresto (sacubitril valsartan sodium hydrate)...read more